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Treatment of coronavirus disease 2019 
(COVID-19), as a new entity lacking sufficient ev-
idence-based pharmacotherapy, was initially based 
in drugs with in-vitro activity against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
such as hydroxychloroquine, azithromycin and 
lopinavir/ritonavir. Each of these drugs is known 
to prolong QT interval [1–3]. This phenomenon is 
of utmost importance, as it is associated with early 
after-depolarizations, which can generate short-
coupled premature action potentials that lead to 
ventricular fibrillation and sudden cardiac death [4]. 
Therefore, it seems mandatory to implement 
monitoring systems, in a scenario where the use 
of portable electrocardiographic-recording devices 
could be useful.
This is an observational prospective study 
in a tertiary hospital. Patients hospitalized for 
confirmed SARS-CoV-2 pneumonia and receiving 
specific treatment with either hydroxychloroquine, 
azithromycin or lopinavir/ritonavir (or combina-
tion) were included. Patients were classified into 
three groups: group 1 received one drug, group 2 
received a combination of two drugs and group 3 
received a combination of three drugs. Patients 
in which the electrocardiogram (ECG) tracing 
obtained with the mobile ECG recording device 
was of poor quality were excluded from the study.
Clinical information and 12-lead ECG record-
ings were collected. Baseline QT interval was 
measured in limb leads using the admission-ECG. 
The patients received pharmacological treatment 
according to center-specific guidelines. Verbal 
informed consent was obtained from patients and 
approval from the ethics committee of our center 
was received. A Kardia-Mobile 6L® (AliveCor, 
Inc., Mountain View, California) was used for ECG 
monitoring. This device, approved by the Food and 
Drug Administration for QT interval monitoring, 
consists of a lightweight 3-electrode hardware ca-
pable of registering a 6-lead ECG and a smartphone 
software application. ECGs were recorded periodi-
cally with the physicians’ criteria. A subset of pa-
tients at early discharge were offered one device to 
daily self-monitoring. Corrected QT (QTc) interval 
was calculated using the Bazett formula. Primary 
outcome was to describe the usefulness of tele-
monitoring in COVID-19 patients for management 
of QT-prolonging drugs by assessing the proportion 
of patients with significant ECG changes that imply 
a change in management. Secondary outcome was 
to evaluate the inter-observer reproducibility of QT 
interval quantification using this gadget.
The Shapiro-Wilk test was used to assess 
normality in continuous variables. Continuous 
variables were compared using the Wilcoxon or 
Kruskal-Wallis tests, as appropriate. The Wilcoxon 
signed-rank test was used for paired measure-
ments. Bilateral p values < 0.05 were considered 
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ability of QTc measurements, 120 random ECGs 
were analysed by two independent cardiologists. 
Intraclass correlation coefficient was obtained 
(two-way random, average measures, absolute 
agreement). Statistical analysis was performed 
using SPSS (IBM Inc., Armonk, NY).
A total of 70 patients fulfilled criteria. Tracings 
obtained with the portable device were of sufficient 
quality to provide an accurate QT interval measure-
ment in 69 of them (98.6%). Mean follow-up was 
6.2 ± 8.4 days. Characteristics of the different 
groups are shown in Table 1. An increase in QTc 
interval was observed in all treatment groups, 
being non-significant in group 1 (group 1: 340 
[320.0–350.0] vs. 418 [384.5–460.5], p = 0.109). 
Significance was reached in both group 2 (408 
[377.2–423.5] vs. 426 [412.0–450.0], p = 0.002) and 
group 3 (394 [373.0–422.5] vs. 435 [405.0–450.0], 
p = 0.001). Eighteen (25.7%) patients developed 
a QTc interval > 450 ms. These patients were 
significantly older (67.5 ± 14.9 vs. 55.0 ± 16.0 
years, p = 0.004) and were more likely diagnosed 
of chronic obstructive pulmonary disease (33.3% 
vs. 5.9%, p = 0.009) and previous cardiopathy (50% 
vs. 13.7%, p = 0.007). Taking into consideration 
the information given by the ECG monitoring de-
vices, physicians adopted a different approach in 
the management of 12 (17.4%) patients. Treatment 
was modified in 9 (13%) patients because of pro-
longation of the QTc interval (1 of them also devel-
oped first degree atrioventricular block, with a PR 
interval up to 280 ms); 2 (2.9%) patients required 
monitoring intensification (1 of them because of 
first degree atrioventricular block and the other 
because of prolongation of the QTc interval) and 
anticoagulation was started in one patient because 
of atrial fibrillation diagnosis.
The subgroup of 16 patients who were given 
a recorder to continue daily monitoring experi-
enced also significant prolongation of the QTc 
interval (381.0 [372.0–401.5] at admission vs. 
424.0 [406.0–436.7] at peak, p = 0.002), with mean 
time to reach the maximum QTc: 2 ± 1.8 days). 
By the end of the monitoring phase, QTc inter-
vals were shorter than those at admission (381.0 
[372.0–401.5] vs. 350.0 [334.2–369.0]; p = 0.019).
Inter-observer intraclass correlation coef-
ficient was 0.824, 95% confidence interval 0.733–
–0.882 (good agreement). 
Herein, is presented one of the first series of 
patients both hospitalized [5, 6] and discharged 
with COVID-19 with electrocardiographic sur-
veillance using a portable ECG recorder [7]. The 
device proved to be useful for ECG monitoring in 
these patients, detecting ECG anomalies of enough 
importance to promote a change in management in 
Table 1. Clinical characteristics and QTc interval evolution in the three treatment groups.
Group 1  
(one drug) 
N = 9 (13.0%)
Group 2  
(two drugs) 
N = 37 (53.6%)
Group 3  
(three drugs) 
N = 23 (33.3%)
P
Clinical characteristics
Age [years] 55.0 ± 18.3 66.0 ± 16.2 58.0 ± 15.8 0.248
Male sex 6 (66.7%) 25 (67.6%) 18 (78.3%) 0.643
Dyslipidemia 5 (55.6%) 9 (24.3%) 7 (30.4%) 0.749
Diabetes 7 (77.8%) 4 (10.8%) 5 (21.7%) 0.525
Hypertension 3 (33.3%) 16 (43.2%) 8 (34.8%) 0.387
Previous cardiopathy 6 (66.7%) 11 (29.7%) 3 (13.0%) 0.305
COPD 7 (77.8%) 6 (16.2%) 1 (8.7%) 0.679
Atrial fibrillation 1 (11.1%) 3 (8.1%) 0 0.297
Mortality 0 4 (10.8%) 0 0.159
QTc interval
QTc interval at admission [ms] 340.0 [320.0–350.0] 408.0 [377.2–423.5] 394.0 [373.0–422.5] 0.039
Maximal QTc interval [ms] 418.0 [384.5–460.5] 426.0 [412.0–450.0] 435.0 [405.0–450.0] 0.085
QTc > 450 ms 3 (33.3%) 9 (24.3%) 6 (26.1%) 0.859
DQTc > 60 ms 1 (11.1%) 4 (15.4%) 3 (9.7%) 0.818
Qualitative variables are shown as number (percentage); quantitative variables are shown as mean ± standard deviation or median [interquartile 
range], as appropriate; COPD — chronic obstructive pulmonary disease
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17.4% of them. These anomalies consisted not only 
in QTc interval prolongation, but also in PR interval 
prolongation and atrial arrhythmias. These small, 
light gadgets allow physicians to quickly perform 
an ECG to a high number of patients, including the 
monitoring of outpatients. These characteristics were 
determinant to ensure safe management in the first 
wave of the COVID-19 pandemic, when an enormous 
number of patients overtook available resources.
The intraclass correlation coefficient points 
a good agreement in the measurements of QTc 
interval using these portable recorders, supporting 
the solidness of this handheld device. Once con-
firmed the value and the reliability of these devices, 
ECG portable recorders are called to be part of the 
workaday armamentarium in our hospitals.
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